Malaria drug could help fight dangerous virus in transplant patients

NCT ID NCT06853184

Recruiting now Disease control Sponsor: Amivas Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 04, 2026 · Updated 3 times

Summary

This study tests whether adding the malaria drug artesunate to standard antiviral treatment can better control cytomegalovirus (CMV) infection in people who have received a solid organ transplant (kidney, lung, heart, or liver). About 90 adult participants will receive either a low or high dose of artesunate plus standard care, or standard care alone. The goal is to see if the combination reduces the amount of virus in the blood more effectively than standard treatment alone.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: artesunate (an antimalarial drug) combined with ganciclovir or valganciclovir (standard antiviral drugs)
What this could lead to: If it works, this could offer a new combination treatment to better control CMV infections in transplant patients, potentially reducing complications.
What could go wrong: This is an early Phase 2 trial with only 90 participants, so results may not apply to everyone. The added benefit of artesunate is unproven, and side effects from the combination are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CMV INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cytomegalovirus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CMV INFECTION

Contacts and locations

Locations

Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States
Mayo Clinic
RECRUITING

Rochester, Minnesota, 55905, United States
Princess Alexandra Hospital
TERMINATED

Woolloongabba, Australia
Westmead Hospital
TERMINATED

Westmead, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.